Anonymous ID: 45b967 May 22, 2020, 10:10 a.m. No.9277463   🗄️.is 🔗kun   >>7701

>>9275923 pb

>>9275959 pb

>>9276018 pb

the devil's always in the details.

>https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31180-6/fulltext

Our study has several limitations. The association of decreased survival with hydroxychloroquine or chloroquine treatment regimens should be interpreted cautiously. Due to the observational study design, we cannot exclude the possibility of unmeasured confounding factors, although we have reassuringly noted consistency between the primary analysis and the propensity score matched analyses. Nevertheless, a cause-and-effect relationship between drug therapy and survival should not be inferred.

 

Declaration of interests

MRM reports personal fees from Abbott, Medtronic, Janssen, Mesoblast, Portola, Bayer, Baim Institute for Clinical Research, NupulseCV, FineHeart, Leviticus, Roivant, and Triple Gene.

SSD is the founder of Surgisphere Corporation.

FR has been paid for time spent as a committee member for clinical trials, advisory boards, other forms of consulting, and lectures or presentations; these payments were made directly to the University of Zurich and no personal payments were received in relation to these trials or other activities.

ANP declares no competing interests.

Anonymous ID: 45b967 May 22, 2020, 10:37 a.m. No.9277701   🗄️.is 🔗kun   >>7714

>>9277463

>>https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31180-6/fulltext

>SSD is the founder of Surgisphere Corporation.

they used data from Surgisphere to do the study.

 

We did a multinational registry analysis of the use of hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19. The registry comprised 671 hospitals located in six continents (appendix p 3). The Surgical Outcomes Collaborative (Surgisphere Corporation, Chicago, IL, USA) consists of de-identified data obtained by automated data extraction from inpatient and outpatient electronic health records, supply chain databases, and financial records. The registry uses a cloud-based health-care data analytics platform that includes specific modules for data acquisition, data warehousing, data analytics, and data reporting. manual data entry process is used for quality assurance and validation to ensure that key missing values are kept to a minimum.

The Surgical Outcomes Collaborative (hereafter referred to as the Collaborative) ensures compliance with the US Food and Drug Administration (FDA) guidance on real-world evidence. Real-world data are collected through automated data transfers that capture 100% of the data from each health-care entity at regular, predetermined intervals, thus reducing the impact of selection bias and missing values, and ensuring that the data are current, reliable, and relevant.

 

The standardised Health Level Seven-compliant data dictionary used by the Collaborative serves as the focal point for all data acquisition and warehousing. Once this data dictionary is harmonised with electronic health record data, data acquisition is completed using automated interfaces to expedite data transfer and improve data integrity. Collection of a 100% sample from each health-care entity is validated against financial records and external databases to minimise selection bias.

The data collection and analyses are deemed exempt from ethics review.